PANRETIN SUMMARY
Panretin®
(alitretinoin)
gel 0.1%
(For topical use only)
Panretin® gel 0.1% contains alitretinoin and is intended for topical application only.
Panretin® gel is indicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma. Panretin® gel is not indicated when systemic anti-KS therapy is required (e.g., more than 10 new KS lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary KS, or symptomatic visceral involvement). There is no experience to date using Panretin® gel with systemic anti-KS treatment.
|
NEWS HIGHLIGHTS
Published Studies Related to Panretin (Alitretinoin Topical)
Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. [2008.04]
Background Patients with severe chronic hand eczema (CHE) refractory to topical corticosteroids currently have limited treatment options suited for chronic use, and few controlled clinical studies have investigated new therapies in this setting. Objectives To assess the efficacy and safety of oral alitretinoin (9-cis retinoic acid) taken at 10 mg or 30 mg once daily for up to 24 weeks, compared with placebo control, in the treatment of severe CHE refractory to topical corticosteroids...
Everolimus: in advanced renal cell carcinoma. [2009]
Everolimus is an orally administered, targeted therapy indicated for the treatment of advanced renal cell carcinoma. It inhibits the mammalian target of rapamycin, an integral component of multiple pathways involved in cell growth and proliferation... The tolerability profile of everolimus was largely manageable in the phase III trial, with most treatment-related adverse events being of grade 1 or 2 severity.
[Alitretinoin: a new treatment option for chronic refractory hand eczema] [2008.09]
About 10% of Germans have chronic hand eczema (CHE).When used for CHE with detailed patient counseling and appropriate laboratory monitoring, alitretinoin is a promising new option for systemic treatment.
Alitretinoin: a comprehensive review. [2008.03]
BACKGROUND: Alitretinoin (9-cis-retinoic acid) is a unique panagonist retinoid, capable of binding to all six known retinoid receptors (RAR-alpha, -beta, -gamma, and RXR-alpha, -beta, -gamma). Studies are being carried out to determine how best to utilize this characteristic in treatments for conditions such as chronic hand dermatitis. OBJECTIVE: To review the literature on alitretinoin... CONCLUSIONS: Orally administered alitretinoin is a safe and effective treatment for chronic hand dermatitis. Topical treatment with alitretinoin can be expanded into other areas such as photoaged skin and cutaneous T-cell lymphoma. Despite these benefits, oral alitretinoin will face a difficult path attaining approval for use in the US.
[Kaposi's sarcoma treated with topical alitretinoin] [2007.01]
Kaposi's sarcoma is a multifocal neoplastic process with four clinical variants, all of them induced by human herpes virus 8. Currently there is no treatment of choice and it depends on the extension and location of the lesions as well as on the clinical type of the disease... We report a case of Kaposi's sarcoma treated with topical alitretinoin that had a favourable evolution in spite of an intense local reaction.
Clinical Trials Related to Panretin (Alitretinoin Topical)
A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients [Completed]
This is a dosage escalation study to estimate the maximum tolerated dose of 9-cis-retinoic
acid given in combination with tamoxifen. Groups of 3 to 6 patients receive oral
9-cis-retinoic acid daily for 4 weeks, after which daily oral tamoxifen is added to the
regimen. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the
study if medically appropriate.
A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma [Completed]
The purpose of this study is to see if ALRT1057 is safe and effective in treating patients
with AIDS-related Kaposi's sarcoma (KS).
A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma [Completed]
The purpose of this study is to see if ALRT1057 gel is safe and effective in treating
Kaposi's sarcoma (KS) when applied to skin .
Alitretinoin in the Treatment of Chronic Hand Eczema [Recruiting]
Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema [Recruiting]
The purpose of this study is to investigate the safety and efficacy of alitretinoin in the
treatment of severe chronic hand eczema that does not respond to treatment with potent
topical steroids.
|
